Poster Presentation 11th Annual Conference of the International Chemical Biology Society 2022

Tyrosinase inhibitors as potential anti-melanoma agents and novel treatment for Parkinson's disease (#145)

Wanli Jin 1 , Christian Fercher 2 , Ye Yuan 1 , Zyta Ziora 1 , Mark Blaskovich 1
  1. Institute for Molecular Bioscience, Brisbane, QLD, Australia
  2. Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD, Australia

The role of human tyrosinase (hTYR), an enzyme participating in the biosynthesis of melanin in the skin and neuromelanin in the brain, is still unclear. Elevated tyrosinase activity could trigger melanoma and PD. Our studies used different enzyme models to investigate the interaction between tyrosinase and inhibitors. We found that the bacterial tyrosinase (bTYR) and the most extensively used model, mushroom tyrosinase (mTYR), are not promising for the screening of genuine human tyrosinase inhibitors. Thus, it is important to optimize the methodology of human tyrosinase expression to produce the transmembrane protein for enzyme inhibition studies and crystallization studies.

 

 

  1. Roulier B, Pérès B, Haudecoeur R. Advances in the design of genuine human tyrosinase inhibitors for targeting melanogenesis and related pigmentations. Journal of Medicinal Chemistry. 2020 Jul 31;63(22):13428-43.
  2. Lai X, Soler-Lopez M, Wichers HJ, Dijkstra BW. Large-scale recombinant expression and purification of human tyrosinase suitable for structural studies. PloS one. 2016 Aug 23;11(8):e0161697.
  3. Shuster V, Fishman A. Isolation, cloning and characterization of a tyrosinase with improved activity in organic solvents from Bacillus megaterium. Journal of molecular microbiology and biotechnology. 2009;17(4):188-200.